Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy

Journal of Medical Virology

Volumn 86, Issue 2, 2014, Pages 224-234

  Alhamlan, F S ^a   Al Ahdal, M N ^a   Khalaf, N Z ^a   Abdo, A A ^b,c   Sanai, F M ^b,d   Al Ashgar, H I ^a   Elhefnawi, M ^e,f   Zaid, A ^g   Al Qahtani, A A ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^e NATIONAL RESEARCH CENTRE   (Egypt)

^f Scientific Institute and Research Academy (SIRA Corp)   (Egypt)

^g MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Genotype 1; Hepatitis C virus; PEG IFN RBV therapy; Saudi Arabia; Sustained virological response

Indexed keywords

CORE PROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRAZOL;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; SAUDI ARABIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS GENE;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

GENOTYPE 1; HEPATITIS C VIRUS; PEG-IFN/RBV THERAPY; SAUDI ARABIA; SUSTAINED VIROLOGICAL RESPONSE;

ADULT; ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; POINT MUTATION; RIBAVIRIN; SAUDI ARABIA; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

EID: 84890140668     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23823     Document Type: Article

References (31)

1. Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, Al-Hamoudi W, Ali SM, Al-Ashgar HI, Al-Mdani A, Albenmousa A, Al Faleh FZ, Al-Anazi M, Khalaf N, Al-Qahtani A. 2013. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 7:533-538.
2. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380.
3. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410.
4. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Miyakawa Y, Kumada H. 2007b. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50:361-368.
5. Basu A, Meyer K, Ray RB, Ray R. 2001. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 288:379-390.
6. Burland TG. 2000. DNASTAR's Lasergene sequence analysis software. Methods Mol Biol 132:71-91.
7. Chevaliez S, Pawlotsky JM. 2006. HCV genome and life cycle.
8. Daw MA, Dau AA. 2012. Hepatitis C virus in Arab world: A state of concern. ScientificWorldJournal 2012:719494.
9. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81:8211-8224.
10. El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, Hotta H. 2012. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology 55:1-11.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
12. Furui Y, Hoshi Y, Murata K, Ito K, Suzuki K, Uchida S, Satake M, Mizokami M, Tadokoro K. 2011. Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors. J Med Virol 83:1924-1929.
13. Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z. 2012. Prediction of response to pegylated-interferon-alpha and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 9:123.
14. Hall T. 1999. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 41:95-98.
15. Henikoff S, Henikoff JG. 1992. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 89:10915-10919.
16. Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H. 2012. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol 47:1143-1151.
17. Korber B, Myers G. 1992. Signature pattern analysis: A method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 8:1549-1560.
18. Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. 2011. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat 18:e117-e125.
19. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358:958-965.
20. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
21. McLauchlan J. 2000. Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes. J Viral Hepat 7:2-14.
22. Nakano T, Lau GM, Sugiyama M, Mizokami M. 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 32:339-345.
23. Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109:187-193.
24. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
25. Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85:3173-3188.
26. Tai AW, Chung RT. 2009. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: A hardwiring issue? J Infect Dis 199:1101-1103.
27. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEG A5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739.
28. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
29. Timm J, Roggendorf M. 2007. Sequence diversity of hepatitis C virus: Implications for immune control and therapy. World J Gastroenterol 13:4808-4817.
30. Tsubota A, Fujise K, Namiki Y, Tada N. 2011. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 17:419-432.
31. Walewski JL, Gutierrez JA, Branch-Elliman W, Stump DD, Keller TR, Rodriguez A, Benson G, Branch AD. 2002. Mutation Master: Profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA 8:557-571.